Axsome Therapeutics has again demonstrated the strength of its intellectual property portfolio, shaking hands with Teva on a settlement in patent-litigation proceedings that will keep the Israeli firm’s proposed generic version of Axsome’s Auvelity (dextromethorphan/bupropion) treatment for major depressive disorder off the market until at least September 2038.
Teva Deals Early On US Auvelity Generic, Agreeing To At Least 13-Year Freeze
Auvelity Shielded By More Than 100 Patents; Peak Sales Tipped To Exceed $2.5bn
Teva will have to wait until the end of the next decade to launch its proposed generic version of Axsome Therapeutics’ Auvelity treatment for MDD.
More from Legal & IP
• By
In a precedential decision, the US Court of Appeals for the Federal Circuit has determined the meaning of the language “the patent” as it applies to patent-term extensions for reissued patents, in the context of Aurobindo’s bid to wipe out a reissued patent shielding Merck & Co’s Bridion (sugammadex) injectable.
• By
Novartis’ multi-front legal battle against MSN Laboratories over its Entresto blockbuster in the US has taken yet another twist, with a federal district court in New Jersey finding that a preliminary injunction was warranted against MSN’s product on the basis of infringement of Novartis’ trade dress.
• By
Walmart has launched an attack on a host of industry-leading generics firms over historical price-fixing allegations, with the US retail giant seeking treble damages from a Pennsylvania district court.
• By
Amgen’s biosimilar aflibercept formulation is keeping it head and shoulders above other would-be Eylea biosimilar competitors, while continuing to frustrate originator Regeneron’s push to block sales of the product while it battles Amgen over alleged infringement of a key US patent.